Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (281-290 of 418) with videos related to

Pageof 42
Sort By:
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2012
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesEleni M Karapanagiotou, Victoria Roulstone, Katie Twigger, et al.
Molecular Cancer Therapeutics|August 10, 2019
Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer TherapyMassimo Masiero, Demin Li, Pat Whiteman, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
British Journal of Cancer|February 14, 2018
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF<sup>V600</sup> mutation-positive melanomaBrigitte Dréno, Paolo A Ascierto, Victoria Atkinson, et al.
Urologic Oncology|December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraGwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
The Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Cancer Cell|April 10, 2023
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaKatie M Campbell, Meelad Amouzgar, Shannon M Pfeiffer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Pageof 42

Showing results (281-290 of 418) with videos related to

Sort By:
Pageof 42
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2012
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesEleni M Karapanagiotou, Victoria Roulstone, Katie Twigger, et al.
Molecular Cancer Therapeutics|August 10, 2019
Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer TherapyMassimo Masiero, Demin Li, Pat Whiteman, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
British Journal of Cancer|February 14, 2018
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF<sup>V600</sup> mutation-positive melanomaBrigitte Dréno, Paolo A Ascierto, Victoria Atkinson, et al.
Urologic Oncology|December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraGwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
The Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Cancer Cell|April 10, 2023
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaKatie M Campbell, Meelad Amouzgar, Shannon M Pfeiffer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
Pageof 42